Vanda Pharmaceuticals Receives U.S. Patent Allowance For PONVORY® (Ponesimod) In The U.S.
Portfolio Pulse from Benzinga Newsdesk
Vanda Pharmaceuticals Inc. has received a notice of allowance from the U.S. Patent and Trademark Office for a patent application related to PONVORY® (ponesimod), which is used in the treatment of multiple sclerosis. The patent covers methods for reducing clinical management events and reinitiating treatment after missed doses, with an anticipated expiration date of October 10, 2042. Vanda plans to list the patent in the FDA's Orange Book upon issuance.
January 26, 2024 | 7:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vanda Pharmaceuticals' allowance for a new PONVORY® patent may strengthen its market position in multiple sclerosis treatments and potentially enhance its long-term revenue prospects.
The allowance of a new patent for PONVORY® is significant for Vanda Pharmaceuticals as it extends the intellectual property protection of a key product in their portfolio. This can prevent competitors from entering the market with similar products and may lead to increased investor confidence in the company's future revenue streams. The listing of the patent in the FDA's Orange Book further solidifies the drug's market exclusivity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100